Chirurgi V A, Edelstein H, Oster S E, Karp R, Cassano K B, Aiken S, McCabe R E
Medical Service, Veterans Administration Medical Center, Martinez, CA 94553.
South Med J. 1994 Sep;87(9):875-80. doi: 10.1097/00007611-199409000-00002.
Teicoplanin, a glycopeptide antibiotic chemically related to the vancomycin-ristocetin group of antibiotics, has potent activity against aerobic and anaerobic gram-positive bacteria. In this study, we examined the efficacy and safety of teicoplanin for parenteral treatment of skin and soft tissue infections caused by gram-positive bacteria. Ninety-six hospitalized adults with moderate to severe skin and soft tissue infections were randomized to receive either teicoplanin intravenously (i.v.) once a day, teicoplanin intramuscularly (i.m.) once a day, or cefazolin i.v. every 8 hours. We evaluated patients' clinical and microbiologic status and assessed clinical and laboratory adverse events. Of 76 clinically assessable patients, 26 of 26 (100%) given teicoplanin i.v., 21 of 22 (95%) given teicoplanin i.m., and 26 of 28 (93%) given cefazolin showed improvement or cure. Of 60 microbiologically assessable patients, 22 of 22 (100%) given teicoplanin i.v., 16 of 18 (89%) given teicoplanin i.m, and 18 of 20 (90%) given cefazolin were cured. Of 96 patients assessable for adverse events, 7 of 34 (21%) given teicoplanin i.v., 4 of 31 (13%) give teicoplanin i.m., and 1 of 31 (3%) given cefazolin had adverse events. In this study, once daily teicoplanin appeared to be safe and effective therapy for skin and soft tissue infections.
替考拉宁是一种糖肽类抗生素，在化学结构上与万古霉素-利托菌素类抗生素相关，对需氧和厌氧革兰氏阳性菌具有强大活性。在本研究中，我们考察了替考拉宁用于胃肠外治疗革兰氏阳性菌引起的皮肤和软组织感染的有效性和安全性。96例患有中重度皮肤和软组织感染的住院成人被随机分为三组，分别接受每日一次静脉注射替考拉宁、每日一次肌肉注射替考拉宁或每8小时静脉注射头孢唑林。我们评估了患者的临床和微生物学状况，并评估了临床和实验室不良事件。在76例可进行临床评估的患者中，26例（100%）接受静脉注射替考拉宁、22例中的21例（95%）接受肌肉注射替考拉宁以及28例中的26例（93%）接受头孢唑林治疗的患者病情有所改善或治愈。在60例可进行微生物学评估的患者中，22例（100%）接受静脉注射替考拉宁、18例中的16例（89%）接受肌肉注射替考拉宁以及20例中的18例（90%）接受头孢唑林治疗的患者被治愈。在96例可评估不良事件的患者中，34例接受静脉注射替考拉宁的患者中有7例（21%）、31例接受肌肉注射替考拉宁的患者中有4例（13%）以及31例接受头孢唑林的患者中有1例（3%）出现了不良事件。在本研究中，每日一次使用替考拉宁似乎是治疗皮肤和软组织感染的安全有效的疗法。
